SCM
CTIC

Segantii Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Segantii Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-24,293
Closed -$102K – 378
2017
Q1 		$102K Buy
+24,293
New +$112K 0.02% 203

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

Segantii Capital Management's CTIC Position: Q2 2017 in Review

Segantii Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2017, closing a stake of 24,293 shares — an estimated $102K sold.

Segantii Capital Management first reported a position in CTIC in Q1 2017 and held it in 1 quarter. The position peaked at $102K in Q1 2017. 40 funds tracked by Wall St. Rank hold CTIC as of Q2 2017.

  • Segantii Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 24,293 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2017, an estimated $102K.
  • Segantii Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $102K in Q1 2017.
  • 40 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.